Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

On Some Issues of Analyzing Handwriting Objects Submitted for Examination in Electronic Form

Autor: V. E. Yaskina, P. I. Lakeev, L. M. Kruglov

Publikováno v: Теория и практика судебной экспертизы, Vol 18, Iss 2, Pp 54-61 (2023)

The article discusses the issues of analyzing objects of handwriting examination provided in electronic form. The authors describe the ways of obtaining such manuscripts and their features determined by the type of the electronic documents submitted

Externí odkaz: https://doaj.org/article/e995cdd4f47e4ce793c11c51e838b8c4

Zobrazit plný text záznamu

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

Autor: L M, Krug, K K, Ng, M G, Kris, V A, Miller, W, Tong, R T, Heelan, L, Leon, D, Leung, J, Kelly, S C, Grant, F M, Sirotnak

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(9)

The 10-deazaaminopterins are a new class of rationally designed antifolates demonstrating greater antitumor effects than methotrexate in murine tumor models and human tumor xenografts. Their design was aimed at improving membrane transport and polygl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::be584f4003fcde6d674955ebd197daa5
https://pubmed.ncbi.nlm.nih.gov/10999734

Zobrazit plný text záznamu

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

Autor: V A, Miller, K K, Ng, L M, Krug, W, Perez, B, Pizzo, R T, Heelan, M G, Kris

Publikováno v: Cancer. 88(5)

With preclinical evidence of synergy, this dose-finding trial examining the combination of docetaxel and vinorelbine given with prophylactic filgrastim for the treatment of patients with nonsmall cell lung carcinoma was undertaken.Twenty-seven patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::42b5989a13000a5422cd1708df29ed0d
https://pubmed.ncbi.nlm.nih.gov/10699893

Zobrazit plný text záznamu

Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer

Autor: L M, Krug, V A, Miller

Publikováno v: Seminars in oncology. 26(5 Suppl 16)

Both vinorelbine and docetaxel are effective as single agents in non-small cell lung cancer, with response rates of 25% to 30%. Several in vitro and in vivo models demonstrate schedule-dependent synergy between these agents. In phase II clinical tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::25e7b4c8a3e39c7e91e2cf92a16f69b0
https://pubmed.ncbi.nlm.nih.gov/10585005

Zobrazit plný text záznamu

Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination

Autor: L M, Krug, S C, Grant, V A, Miller, K K, Ng, M G, Kris

Publikováno v: Seminars in oncology. 26(5 Suppl 15)

In the last 25 years, treatment for small cell lung cancer (SCLC) has improved with advances in chemotherapy and radiotherapy. Standard chemotherapy regimens can yield 80% to 90% response rates and some cures when combined with thoracic irradiation i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ee91476d9e71aeaeb4ac9911a415e864
https://pubmed.ncbi.nlm.nih.gov/10566613

Zobrazit plný text záznamu

Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer

Autor: L. Schwartz, L. M. Krug, N. A. Rizvi, M. G. Kris, Binsheng Zhao, N. Rizk, E. Senturk, V. Rusch, Robert J. Downey, Matthew G. Fury

Publikováno v: Journal of Clinical Oncology. 25:18045-18045

18045 Background: Bevacizumab (Bev) improves response and survival in patients with advanced non-squamous lung cancer with chemotherapy however there are limited data as single agent therapy and in early stage NSCLC. Methods: Patients with resectable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3610b57e4294f18cc448cce3c0e5c555
https://doi.org/10.1200/jco.2007.25.18_suppl.18045

Zobrazit plný text záznamu

Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

Autor: C. G. Azzoli, N. A. Rizvi, W. Pao, V. A. Miller, Gregory J. Riely, R. T. Heelan, D. T. Milton, E. Moore, L. M. Krug, M. G. Kris

Publikováno v: Journal of Clinical Oncology. 25:7575-7575

7575 Background: Most non-small cell lung cancers (NSCLC) are primarily resistant to the EGFR tyrosine kinase inhibitor gefitinib. One strategy to overcome resistance is to block parallel or downstream effectors that maintain tumor growth and prolife

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f299a721136a55a37a23d1831139f60b
https://doi.org/10.1200/jco.2007.25.18_suppl.7575

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání